Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 11, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration ( FDA ) for a Phase 1b adaptive dose-finding clinical study of ARO-HIF2, the
View HTML
Toggle Summary Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 6, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on December 6, 2019 it closed the previously announced underwritten public offering of 4,600,000 shares of its common stock, which included shares issued upon the exercise in full
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 4, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $58.00 per share, before underwriting discounts.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 2, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced its intention to offer and sell 4,000,000 shares of its common stock in an underwritten offering pursuant to its existing automatic shelf registration statement.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 26, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Jaffray 31st Annual Healthcare Conference – New York , December 3-5, 2019 December 3 , 11:00 a.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results
- Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Nov. 25, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2019 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019
- Company Expects to Initiate Phase 3 Clinical Trials Next Year PASADENA, Calif. --(BUSINESS WIRE)--Nov. 18, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented updated Phase 1 clinical data on its two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Planned Management Transition
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 15, 2019-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Bruce Given , M.D., Arrowhead’s chief operating officer and head of R&D, plans to retire on May 1, 2020 , after a more than 30 year career in biotechnology and pharmaceutical
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 11, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2019 , at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2019 .
View HTML
Toggle Summary Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 8, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced Phase 2 clinical data on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA), and the first clinical data on a triple combination of JNJ-3989, JNJ-6379,
View HTML